<DOC>
	<DOCNO>NCT00335166</DOCNO>
	<brief_summary>This multicenter , randomize , double blind , parallel group study 6 month ' treatment SLV308 monotherapy patient early stage PD . An open label safety extension study plan separate protocol patient willing eligible participate .</brief_summary>
	<brief_title>SLV 308 Pramipexole Treatment Patients With Early Parkinson Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Diagnosis idiopathic Parkinson 's Disease , Modified Hoehn &amp; Yahr stage III , UPDRS motor score ( part III ) must total least 10 baseline . Diagnosis unclear suspicion parkinsonian syndrome , Patients undergone surgery treatment PD , Current presence dyskinesia , Motor fluctuation loss postural reflex , A history nonresponse adequate course ldopa dopamine agonist , Patients previously treatment dopamine agonist need terminate induction psychosis ( i.e . hallucination ) /or sleep attack .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Parkinson Disease</keyword>
</DOC>